Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML
نویسندگان
چکیده
منابع مشابه
Treatment of Low-Blast Count AML using Hypomethylating Agents
In 2002, the WHO classification reduced the proportion of blasts in the bone marrow (BM) necessary for the diagnosis of acute myeloid leukemia (AML) from 30% to 20%, eliminating the RAEB-t subtype of myelodysplastic syndromes (MDS). However, this AML subtype, defined as low-blast count AML (LBC-AML, with 20-30% BM-blasts) is characterized by peculiar features, as increased frequency in elderly ...
متن کاملAML cytogenetics: the complex just got simpler.
In this issue of Blood, Middeke et al, for the well-regarded Cooperative German Study Group, report a retrospective analysis in which they demonstrate that a hierarchial classification system for specific cytogenetic abnormalities in acute myeloid leukemia (AML) reveals that patients with abnormal 17p [abnl(17p)] and -5/5q- abnormalities have worse outcomes after allogeneic hematopoietic cell t...
متن کاملThe Difference in Initial Leukocyte Count, Bone Marrow Blast Cell Count and CD 34 Expression in Patients with Acute Myeloid Leukemia with and without NPM1 gene Mutation
Background: Mutation in NPM1 gene has been reported to be the most common genetic mutation in de novo acute myeloid leukemia (AML). AML with NPM1 gene mutation usually presents with higher initial leukocyte and blast cell counts and negative CD34 expression. We aimed to investigate the difference of initial leukocyte counts, bone marrow blast cell counts and expression of CD34 among patients wi...
متن کاملLow levels of ABCG2 expression in adult AML blast samples.
Previous reports have suggested that the adenosine triphosphate-binding cassette protein ABCG2 (breast cancer resistance protein [BCRP], mitoxantrone resistance [MXR]) is associated with drug resistance in acute myeloid leukemia (AML). The aims of this study were to determine the level of ABCG2 mRNA expression necessary to produce drug resistance and to define the ABCG2 levels in normal bone ma...
متن کاملA new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
BACKGROUND AND OBJECTIVES To refine cytogenetically based risk-stratification in acute myeloid leukemia (AML). DESIGN AND METHODS Stratification was improved by combining cytogenetics and day 16 bone marrow blasts and by subdividing unfavorable cytogenetics. The new score identifying five prognostically different groups was developed in 321 patients (AMLCG 1992 trial) and subsequently validat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biology of Blood and Marrow Transplantation
سال: 2015
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2014.11.483